癌症是目前死亡率仅次于心脑血管疾病的第2号杀手,近年来肿瘤治疗已取得较大进展,但临床使用的抗肿瘤药物仍既杀伤肿瘤细胞又杀伤正常细胞,对人体多种器官造成严重损害,限制了抗肿瘤药物的应用和发展。开发有效的抗癌辅助药以提高癌症治疗的效果,已成为世界各国医药界极其关注的问题。选择性细胞保护剂阿米福汀由美国研制已在多个国家上市,我国研制开发的此产品也已投放市场。 1 化学名称 阿米福汀(Amifostine)是一种 Cancer is currently the No. 2 killer of cardiovascular mortality after the recent cancer treatment has made great progress, but the clinical use of antitumor drugs still kill both tumor cells and normal cells, a variety of human organs Causing serious damage, limiting the application and development of anti-cancer drugs. The development of effective anti-cancer adjuvant drugs to improve the efficacy of cancer treatment has become the world’s pharmaceutical sector is extremely concerned about the issue. Selective cytoprotective agent amifostine developed by the United States has been listed in many countries, China has developed this product has also been put on the market. 1 The chemical name Amifostine is one